Sponsor Deadline
Posted: 4/18/2022

Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus

NCATS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the COVID-19. NCATS is especially interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

This Notice announces the availability of competitive revisions for investigators and institutions funded through:

  • The NIH Microphysiological Systems (MPS) Program; or
  • SBIR/STTR-supported investigators, provided the award involves tissue chips; or
  • Microphysiological systems programs from across NIH.

Applications will be accepted on a rolling basis from May 15, 2020 to January 25, 2022 by 5:00 PM local time of the applicant organization. This NOSI expires on January 26, 2022. An application submitted in response to this NOSI that is received on/after the expiration date will be withdrawn.

Areas of Interest

NCATS will accept the submission of applications for Competitive Revisions to active grants to address only the following research areas of interest:

  • Incorporation of new and emerging data related to SARS-CoV-2 into ongoing research efforts to develop microphysiological systems/tissue chips models for COVID-19
  • Use of microphysiological systems/tissue chips or evaluating, repurposing or modification of diagnostic tools to enable rapid detection of COVID-19 infection
  • Use of microphysiological systems/tissue chips for the rapid development and assessment of potential therapeutic agents for COVID-19

 

Applications that are not responsive to the above research areas of interest will be withdrawn without review.

A multi-organ on chip approach is strongly encouraged though not required. Please document access to a BSL-3 facility or include scientific justification for use of alternative facilities, for example using an engineered a COVID-19 pseudovirus that expresses the key surface Spike protein, which mediates its entry into cells.

Amount Description